SF1126 / SignalRx - LARVOL DELTA

Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=7 | Terminated | Sponsor: SignalRX Pharmaceuticals, Inc. | N=14 ➔ 7 | Active, not recruiting ➔ Terminated; Lack of recruitment and sponsor's priority changes

Combination therapy • Enrollment change • Trial termination • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Oncology • Solid Tumor

Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma. (PubMed, J Pediatr Hematol Oncol) - "In vivo, SF1126 showed a significant reduction in tumor volume. These results suggest that dual PI3K/BRD4 inhibitor, SF1126, has antitumor activity in ES models."

Journal • Ewing Sarcoma • Oncology • Osteosarcoma • Pediatrics • Sarcoma • Solid Tumor

Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. (PubMed, Oncotarget) - "Finally, treatment of neuroblastoma tumors with SF1126 inhibited neuroblastoma growth in vivo. These data suggest integrin αvβ3, MYCN/BRD4 and PTEN/PI3K/AKT signaling as biomarkers and hence therapeutic targets in neuroblastoma and support testing of the RGD integrin αvβ3-targeted PI-3K/BRD4 inhibitor, SF1126 as a therapeutic strategy in this specific subgroup of high risk neuroblastoma."

Biomarker • Journal • Biosimilar • Neuroendocrine Tumor • Oncology • Solid Tumor

Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies (ASCO 2011) - Presentation time: Sat, Jun 4, 2:00pm to 6:00pm; P1, N=39; SF1126 was tolerated at doses up to 1,110mg/m2 given by i.v. infusion twice weekly & showed significant disease stabilization in multiple solid tumor pts; MTD was not reached; In B-cell malignancies promising preliminary activity alone & in concert with rituximab was noted

Oncology

An In silico Approach to Identify High Affinity Small MoleculenTargeting m-TOR Inhibitors for the Clinical Treatment ofnBreast Cancer (PubMed, Asian Pac J Cancer Prev) - "...of mTOR against breast cancer, SF1126 was identified to have the best docking score of -8.705, using Schrodinger...ligand and receptor protein with the pharmacophore mapping showed the best conjugates, and the ZINC85569445 canbe further studied for future benefits of treatment of breast cancer."

Clinical • Journal

Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1; N=14; Active, not recruiting; Sponsor: SignalRX Pharmaceuticals, Inc.; Recruiting ➔ Active, not recruiting; Trial primary completion date: Oct 2022 ➔ Apr 2019

Clinical • Combination therapy • Enrollment closed • Trial primary completion date

Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo. (PubMed, Cell Physiol Biochem) - "SF1126 inhibits CRC cell growth possibly by targeting PI3K-Akt-mTOR, BRD4, and p38 signaling."

Journal • Preclinical